Total Cost
Free shipping on all orders
To place an order please call (833) 812 - 0565

neomyc-polym-dexameth eye drop generic maxitrol

In stock Manufacturer VALEANT/BAUSCH 24208083060
$22.85 / 5 Milliliters Drop Btl

Select Quantity

Prescription is required


Neomycin is used topically in combination with other anti-infective agents for the short-term treatment of superficial infections of the eye caused by susceptible bacteria.

Neomycin is used in combination with other anti-infective agents and corticosteroids for the treatment of corticosteroid-responsive ocular conditions when a corticosteroid is indicated and a bacterial infection or risk of infection exists.

Neomycin is used in combination with other anti-infective agents and corticosteroids for the treatment of otitis externa caused by susceptible bacteria.

For other uses of neomycin, see 8:12.02 and see 84:04.04.

Dosage and Administration


Ophthalmic Infections

In combination with various drugs, neomycin sulfate is applied to the eye in the form of ophthalmic ointments, solutions, or suspensions. When administering neomycin ophthalmic preparations, care should be taken to avoid contamination of the tip of the dropper or ointment tube.

Otic Infections

Neomycin sulfate, in combination with various drugs, is instilled into the external ear in the form of otic solutions or suspensions. For topical therapy of the external ear to be most effective, the ear canal should be clean and dry.


Ophthalmic Infections

A small amount of an ointment containing neomycin may be placed into the conjunctival sac 1 or more times daily every 3-4 hours. When solutions or suspensions are used, 1 or 2 drops are instilled onto the affected eye every 3-4 hours, or more frequently, as necessary.

Otic Infections

Otic preparations should be used sparingly to prevent accumulation of excess debris in the ear canal and usually are administered 3 or 4 times daily. Therapy should be limited to 10 days.


Adverse Effects

Topical neomycin is a contact sensitizer, especially when used for prolonged periods of time. Sensitivity to topical neomycin has been reported to occur in 5-15% of patients treated with the drug. Hypersensitivity reactions including contact conjunctivitis, burning, erythema, rash, and urticaria have occurred following topical application of neomycin to patients who are sensitive to the drug or other ingredients in the formulations. If hypersensitivity occurs, neomycin should be discontinued. Patch testing may be useful in diagnosing allergic contact dermatitis to neomycin. To minimize the possibility of false-negative responses, some clinicians recommend testing with 20% neomycin sulfate in petrolatum.

Instillation of neomycin into the ear of patients undergoing tympanoplasty has caused ototoxicity.

Precautions and Contraindications

Neomycin sulfate should be administered with caution to patients with otitis externa complicated by chronic otitis media or by a perforated tympanic membrane because of possible absorption of the drug leading to ototoxicity. Ototoxicity, nephrotoxicity, and neuromuscular blockade have occurred following topical application of neomycin, especially in patients undergoing peritoneal instillation, irrigation of wounds or surgical sites, or those receiving treatment for skin ulcers, granulating wounds, burns, or extensive areas of denuded skin. Following systemic absorption of neomycin, toxicity is most likely to occur in patients with renal impairment. The possibility of cumulative toxicity should be considered when neomycin is applied topically in combination with systemic aminoglycoside therapy. Patients using ophthalmic preparations containing neomycin sulfate should be advised to consult a physician if ocular pain, redness, swelling, or irritation worsens or persists. Patients also should be advised to seek their physician's advice immediately regarding the continued use of ophthalmic preparations containing neomycin sulfate if an intercurrent ocular condition (e.g., trauma, infection) occurs.

Because benzalkonium chloride may be absorbed by soft contact lenses, patients receiving ophthalmic preparations that contain this preservative should be advised to wait at least 15 minutes after instillation of the ophthalmic preparation before they insert their contact lenses.

Topical corticosteroids, when used in combination with neomycin, may mask the clinical signs of bacterial, fungal, or viral infections, or may suppress hypersensitivity reactions to the antibiotic or other ingredients in the formulations. The possibility of corticosteroid-induced adverse ocular effects, including increased intraocular pressure, glaucoma, delayed wound healing, and cataract formation, also must be considered. When neomycin is used in fixed combination with a corticosteroid, other cautions, precautions, and contraindications associated with EENT corticosteroids also must be considered in addition to those associated with the anti-infective. In addition, such fixed combinations are contraindicated following uncomplicated removal of a corneal foreign body.

The use of neomycin may result in overgrowth of nonsusceptible organisms including fungi. If superinfection occurs during neomycin therapy, the drug should be discontinued and appropriate therapy instituted.

Although some ophthalmic ointment vehicles used in the past were reported to retard corneal wound healing, currently used ophthalmic ointment vehicles do not appear to slow the rate of corneal wound healing; in addition, ointments may provide a protective effect if the cornea is exposed. However, the manufacturers caution that ophthalmic ointments have retarded corneal healing.

Some commercially available otic formulations of neomycin sulfate contain sulfites that can cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in certain susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low; such sensitivity appears to occur more frequently in asthmatic than in nonasthmatic individuals.

Neomycin ophthalmic and otic preparations are contraindicated in patients who are hypersensitive to the drug or any ingredients in the formulations. Cross-allergenicity among the aminoglycosides has been demonstrated, and the possibility that patients who become sensitized to topical neomycin also may be sensitive to other topical and/or systemic aminoglycosides should be considered.


Studies in rabbits suggest that neomycin is absorbed into the aqueous humor following topical instillation onto the eye of a neomycin sulfate solution containing 40 mg/mL; absorption of the drug is greatest when the cornea is abraded. In dogs, neomycin is absorbed through the ear, especially when applied to the ear canals of dogs with perforated tympanic membranes.

Write Your Own Review

Your meds on autopilot. Forever.